Viewing Study NCT06615206

Home

Certify Doc

Genes

Clinical Trials

CompTox

DrugMatrix

Open Targets

Products

Support

Bugs

Main Search Make This Study a Gene Therapy Make This Study a Not Gene Therapy Report Bug

Ignite Creation Date: 2025-12-26 @ 4:02 PM

Ignite Modification Date: 2025-12-30 @ 5:36 AM

Study NCT ID: NCT06615206

Status: RECRUITING

Last Update Posted: 2024-11-26

First Post: 2024-09-04

Is Gene Therapy: True

Has Adverse Events: False

Brief Title: A First-in-Human Clinical Trial to Evaluate the Safety, Tolerability, and Efficacy of a Novel CRISPR RNA-editing Therapy in Patients with Mecp2 Duplication Syndrome, a Rare Orphan Disease (HERO)

Sponsor: HuidaGene Therapeutics Co., Ltd.

Organization:

Overview Dates Organization Conditions Design Enrollment Locations Outcomes Modules Raw JSON

Study Modules

Identification Module Status Module Sponsor Collaborators Module Oversight Module Description Module Conditions Module Design Module Arms Interventions Module Outcomes Module Eligibility Module Contacts Locations Module